// App-Quantinova.ai

2085 : Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Researchers

Presenter

  • Timothy H. J. Goodship

Principal Investigators

  • Richard J. H. Smith

  • Christophe M. Legendre

  • Christoph Licht

  • Petra Muus

  • Camille L. Bedrosian

  • Veronique Fremeaux-Bacchi

  • Chantal Loirat

Medical Centers

  • Hospital for Sick Children, Toronto, ON, Canada

  • Assistance Publique -Hopitaux Paris, Hopital Robert-Debre, Paris, France

  • Radboud University Medical Center, Njmegen, Netherlands

  • Hopital European Georges Pompidou, Paris, France

  • University Paris Descartes & Hopital Necker, Paris, France

Locations

  • France

  • Canada

  • Netherlands

Companies

  • Alexion Pharmaceutic

Study Components

Therapeutic Area

  • Nephrology

  • Blood/haematological Diseases

Disease

  • Atypical hemolytic uremic syndrome

  • Thrombotic microangiopathy

  • Hemolytic–uremic syndrome

  • Microvascular complications of diabetes 1

  • End stage renal disease

  • Renal disease

Biomarkers

  • Platelet count

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved